Thérapies de Conversion

Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.

Cancer Immunol Immunother . 2025;74 (10) :302

Résumé

OBJECTIVES: To evaluate the efficacy of combining PD-1 inhibitors with chemotherapy in conversion therapy for patients with stage IV gastric cancer and to determine the populations most likely to benefit from this regimen.METHODS: Data from patients with stage IV gastric cancer who received conversion therapy with PD-1 inhibitors combined with chemotherapy between January 2018 and December 2022 at multiple centers were retrospectively reviewed. Patients who underwent conversion surgery were categorized into a surgery group, while those who did not were placed into a palliative group. The survival outcomes between the two groups and the potential biomarkers that may predict the effectiveness of combining PD-1 inhibitors with chemotherapy were analyzed.RESULTS: A total of 105 patients were included in the analysis, with 48 patients in the surgery group and 57 patients in the palliative group, resulting in a conversion rate of 45.7%. R0 resection was performed in 40 patients (83.3%) in the surgery group. The median survival time (MST) was not reached in the surgery group, while it was 12.0 months in the palliative group (P 

Tous les articles
Loading…
Loading the web debug toolbar…
Attempt #